Medopad and Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a strategic partnership to validate, scale and potentially commercialise the ReVeRe platform as a novel digital biomarker for Alzheimer's disease (AD). Johnson & Johnson Innovation Limited facilitated the deal. The ReVeRe...